187 patents
Page 2 of 10
Utility
FGFR3 Antibodies and Methods of Use
28 Sep 23
Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided.
Yves SABBAGH, Yangde CHEN, William BRONDYK, Huawei QIU, Sunghae PARK, Ronnie WEI, Yu QIU, Yanfeng ZHOU, Cendrine LEMOINE, HyunSuk CHO
Filed: 12 Oct 22
Utility
Flare (Flow Cytometry Attenuated Reporter Expression) Technology for Rapid Bulk Sorting
28 Sep 23
Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS).
Victor R. Cairns, Jose Ignacio Sancho Chavida, Christine DeMaria
Filed: 10 Mar 23
Utility
Methods of Processing a Fluid
21 Sep 23
Provided herein are methods of processing a fluid comprising a recombinant therapeutic protein that include the use of a bioprocessing system comprising integrated unit operations, including cell removal, cell retention, chromatography, virus inactivation, virus filtration, TFF, and formulation.
Michael Coolbaugh, Shashi Malladi
Filed: 24 Feb 23
Utility
Gene Therapy for Niemann-pick Disease Type a
14 Sep 23
This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).
Marco A. PASSINI, Robin J. ZIEGLER, James C. DODGE, Lamya SHIHABUDDIN, Seng H. CHENG
Filed: 8 Mar 23
Utility
Analytical Ultracentrifugation for Characterization of Recombinant Viral Particles
14 Sep 23
Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation.
Catherine R. O'RIORDAN, Brenda Burnham
Filed: 22 Mar 23
Utility
Compositions and Methods for Treating Late-onset Pompe Disease
17 Aug 23
The present application provides methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa.
Patrick FINN, Alaa HAMED, Kristina AN HAACK, Catherine WILSON
Filed: 11 Jun 21
Utility
Eclitasertib for Use In Treating Conditions Involving Systemic Hyperinflammatory Response
27 Jul 23
This disclosure relates to the field of therapeutic protein kinase inhibitors, in particular receptor-interacting protein kinase 1 (“RIPK1”) inhibitor for treatment of subjects with conditions involving systemic hyperinflammatory responses, such as Cytokine Release Syndrome (CRS), or Systemic Inflammatory Response Syndrome (SIRS), sepsis, organ damage, or hyperinflammatory state associated with infectious diseases.
John CAMINIS, Peter FLORIAN, Keith HARRIS, Dimitry OFENGEIM, Sabine SCHNYDER, Heribert STAUDINGER, Matija ZELIC
Filed: 16 Apr 21
Utility
Methods and Compositions for Treating a Bleeding Event In a Subject Having Hemophilia
25 May 23
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).
Akin Akinc
Filed: 1 Aug 22
Utility
Arylamides and Methods of Use Thereof
25 May 23
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof.
Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma
Filed: 3 Jun 22
Utility
Arylamides and Methods of Use Thereof
25 May 23
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof.
Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Joseph Kim, Martin Smrcina, Nina Ma, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet
Filed: 3 Jun 22
Utility
CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
18 May 23
The invention provides a crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, methods of inhibiting tropomyosin-related kinase and/or c-FMS, and methods of treating medical diseases and conditions, such as pain.
Benoit ROBERT
Filed: 11 Nov 22
Utility
Treatment of Osteogenesis Imperfecta
11 May 23
The present disclosure provides methods for treating and improving b1osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGF-β).
Panteleimon D. MAVROUDIS, Nikhil PILLAI, Qingping WANG
Filed: 31 Oct 22
Utility
Arylamides and Methods of Use Thereof
11 May 23
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof.
Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Martin Smrcina, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet, Andrew Scholte
Filed: 3 Jun 22
Utility
Gene Therapy For Neurodegenerative Disorders
4 May 23
Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
Filed: 10 Nov 22
Utility
6-MEMBERED Heteroarylaminosulfonamides for Treating Diseases and Conditions Mediated by Deficient CFTR Activity
4 May 23
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof.
Zhongli Gao, Gregory Hurlbut, Mark Munson, Junkai Liao
Filed: 11 May 22
Utility
Thyroid Stimulating Hormone Compositions
27 Apr 23
Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH.
Clark PAN, Huawei QIU, Sunghae PARK
Filed: 23 May 22
Utility
TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS
16 Mar 23
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease.
John L. Kane, JR., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
Filed: 8 Aug 22
Utility
Antibodies to TGF-Beta
16 Mar 23
The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ) and uses thereof.
Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
Filed: 16 Sep 22
Utility
Gene Therapy For Neurodegenerative Disorders
16 Mar 23
Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
Marco A. PASSINI, Lamya Shihabuddin, Seng H. Cheng
Filed: 13 Oct 22
Utility
Anti-tgf-beta Antibody Formulations and Their Use
2 Feb 23
The present disclosure provides pharmaceutical compositions comprising anti-TGF-β antibodies and methods of use thereof.
Kiran Rana BANGARI, Ramil LATYPOV, Timothy MCCOY, Sanket PATKE
Filed: 17 Jun 22